Management and Characteristics of Embolism and Thrombosis After COVID-19 Vaccination: Scoping Review

References

• Avila J, Long B, Holladay D, Gottlieb M. Thrombotic complications of COVID-19. Am J Emerg Med. 2021;39:213–218. doi:10.1016/j.ajem.2020.09.065
   PubMed Web of Science ®Google Scholar
• Dyer O. Covid-19: US reports low rate of new infections in people already vaccinated. BMJ. 2021;373:n1000. doi:10.1136/bmj.n1000
   PubMedGoogle Scholar
• Shahcheraghi SH, Ayatollahi J, Aljabali AA, et al. An overview of vaccine development for COVID-19. Ther Deliv. 2021;12(3):235–244. doi:10.4155/tde-2020-0129
   PubMed Web of Science ®Google Scholar
• World Health Organization. Listings of WHO’s response to COVID-19; March 26, 2023. Available from: https://www.who.int/news/item/29-06-2020-covidtimeline. Accessed March 26, 2023.
   Google Scholar
• World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19); March 26, 2023. Available from: https://apps.who.int/iris/bitstream/handle/10665/342999/WHO-2019-nCoV-TTS-2021.1-eng.pdf. Accessed March 26, 2023.
   Google Scholar
• Olivieri B, Betterle C, Zanoni G. Vaccinations and autoimmune diseases. Vaccines. 2021;9(8):815. doi:10.3390/vaccines9080815
   Web of Science ®Google Scholar
• Tricco AC,et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets; March 26, 2023. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood. Accessed March 26, 2023.
   Google Scholar
• National Center for Biotechnology Information. Embolism and thrombosis; March 26, 2023. Available from: https://www.ncbi.nlm.nih.gov/mesh/68016769. Accessed March 26, 2023.
   Google Scholar
• Munn Z, Barker T Hugh, Moola S, et al. Methodological quality of case series studies. JBI Database of Systematic Reviews and Implementation Reports. 2019;18(10):2127–2133. doi:10.11124/JBISRIR-D-19-00099
   Google Scholar
• Joanna Briggs Institute. Critical appraisal tools; March 26, 2023. Available from: https://jbi.global/critical-appraisal-tools. Accessed March 26, 2023.
   Google Scholar
• Al-Maqbali JS, Al Rasbi S, Kashoub MS, et al. A 59-year-old woman with extensive deep vein thrombosis and pulmonary thromboembolism 7 days following a first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine. Am J Case Rep. 2021;22:e932946. doi:10.12659/AJCR.932946
   PubMed Web of Science ®Google Scholar
• Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet. 2021;397(10285):e11. doi:10.1016/S0140-6736(21)00872-2
   PubMed Web of Science ®Google Scholar
• D’Agostino V, Caranci F, Negro A, et al. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration. J Pers Med. 2021;11(4):285. doi:10.3390/jpm11040285
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. doi:10.1056/NEJMoa2104840
   PubMed Web of Science ®Google Scholar
• Haakonsen HB, Nystedt A. Deep vein thrombosis more than two weeks after vaccination against COVID-19. Tidsskr nor Laegeforen. 2021. 141. doi:10.4045/tidsskr.21.0274
   Web of Science ®Google Scholar
• Mehta PR, Apap Mangion S, Benger M, et al. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - a report of two UK cases. Brain Behav Immun. 2021;95:514–517. doi:10.1016/j.bbi.2021.04.006
   PubMed Web of Science ®Google Scholar
• Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–2130. doi:10.1056/NEJMoa2104882
   PubMed Web of Science ®Google Scholar
• Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202–2211. doi:10.1056/NEJMoa2105385
   PubMed Web of Science ®Google Scholar
• See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. J Am Med Assoc. 2021;325(24):2448–2456. doi:10.1001/jama.2021.7517
   PubMed Web of Science ®Google Scholar
• Suresh P, Petchey W. ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep. 2021;14(6):e243931. doi:10.1136/bcr-2021-243931
   PubMedGoogle Scholar
• Wolf ME, Luz B, Niehaus L, Bhogal P, Bazner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 vaccine AstraZeneca” exposure. J Clin Med. 2021;10(8):1599. doi:10.3390/jcm10081599
   PubMed Web of Science ®Google Scholar
• Zakaria Z, Sapiai NA, Ghani ARI. Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine. Acta Neurochi. 2021;163(8):2359–2362. doi:10.1007/s00701-021-04860-w
   PubMed Web of Science ®Google Scholar
• World Health Organization. ICD-10 Version: 2016; March 26, 2023. Available from: https://icd.who.int/browse10/2016/en. Accessed March 26, 2023.
   Google Scholar
• Moher D. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med. 2009;151(4):264. doi:10.7326/0003-4819-151-4-200908180-00135
   PubMed Web of Science ®Google Scholar
• Gialeraki A, Valsami S, Pittaras T, Panayiotakopoulos G, Politou M. Oral contraceptives and HRT Risk of thrombosis. Clin Appl Thromb Hemost. 2018;24(2):217–225. doi:10.1177/1076029616683802
   PubMed Web of Science ®Google Scholar
• Johns Hopkins Medicines. Thrombosis; March 26, 2023. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/thrombosis. Accessed March 26, 2023.
   Google Scholar
• Pishko AM, Cuker A. Thrombosis after vaccination with messenger RNA-1273: is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia syndrome? Ann Intern Med. 2021;174(10):1468–1469. doi:10.7326/m21-2680
   PubMed Web of Science ®Google Scholar
• Izak M, Bussel JB. Management of thrombocytopenia. F1000Prime Rep. 2014;6:45. doi:10.12703/p6-45
   PubMedGoogle Scholar
• Martín-Martos F, Trujillo-Santos J, Del Toro J, et al. Gender differences in patients with venous thromboembolism and five common sites of cancer. Thromb Res. 2017;151(Suppl 1):S16–s20. doi:10.1016/s0049-3848(17)30061-0
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. CDC endorses ACIP’s updated COVID-19 vaccine recommendations; March 26, 2023. Available from: https://www.cdc.gov/media/releases/2021/s1216-covid-19-vaccines.html. Accessed March 26, 2023.
   Google Scholar
• Cuker TEWA COVID-19: vaccine-induced immune thrombotic thrombocytopenia (VITT). Wolters Kluwer; March 26, 2023. Available from: https://www.uptodate.com/contents/covid-19-vaccine-induced-immune-thrombotic-thrombocytopenia-vitt. Accessed March 26, 2023.
   Google Scholar
• Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534–537. doi:10.1002/ajh.26132
   PubMed Web of Science ®Google Scholar
• Ulivi L, Squitieri M, Cohen H, Cowley P, Werring DJ. Cerebral venous thrombosis: a practical guide. Pract Neurol. 2020;20(5):356–367. doi:10.1136/practneurol-2019-002415
   PubMedGoogle Scholar
• Furie KL, Cushman M, Elkind MSV, Lyden PD, Saposnik G. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke. 2021;52(7):2478–2482. doi:10.1161/strokeaha.121.035564
   PubMed Web of Science ®Google Scholar
• Krajíčková D, Klzo L, Krajina A, Vyšata O, Herzig R, Vališ M. Cerebral venous sinus thrombosis: clinical characteristics and factors influencing clinical outcome. Clin Appl Thromb Hemost. 2016;22(7):665–672. doi:10.1177/1076029615576739
   PubMed Web of Science ®Google Scholar
• Mayo Clinic. Deep vein thrombosis (DVT); March 26, 2023. Available from: https://www.mayoclinic.org/diseases-conditions/deep-vein-thrombosis/symptoms-causes/syc-20352557. Accessed March 26, 2023.
   Google Scholar
• Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med. 2021;16(3):803–804. doi:10.1007/s11739-021-02685-0
   PubMed Web of Science ®Google Scholar
• Public Health Ontario. Severe outcomes among confirmed cases of COVID-19 following vaccination in Ontario: December 14, 2020 to February 26, 2023; March 26, 2023. Available from: https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-epi-confirmed-cases-post-vaccination.pdf?la=en. Accessed March 26, 2023.
   Google Scholar
• Bussel JB, Connors JM, Cines DB, et al. Vaccine-induced immune thrombotic thrombocytopenia. American Society of Hematology; March 26, 2023. Available from: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia. Accessed March 26, 2023.
   Google Scholar
• NIf H, Excellence C. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT); 2021.
   Google Scholar
• Thrombosis ISo, Haemostasis. ISTH interim guidance for the diagnosis and treatment on vaccine‐induced immune thrombotic thrombocytopenia; 2021.
   Google Scholar
• World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on vaccine safety on AstraZeneca COVID-19 vaccine. Saudi Med J. 2021;42(5):581–582.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes emergency use of Novavax COVID-19 vaccine, adjuvanted; March 26, 2023. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted. Accessed March 26, 2023.
   Google Scholar